Slide 1: A Specialty Life Sciences Company
A SPECIALTY LIFE SCIENCES COMPANY Corporate Presentation MAY 2025 OTCQB: FRANKFURT: RVVTF 31R Revive Therapeutics Ltd. | Office: 1-888-901-0036 | E-mail: info@revivethera.com
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS Certain statements contained in this presentation constitute forward-looking information within the meaning of securities laws. Forward- looking information may relate to our future outlook and anticipated events or results and may include statements regarding o ur future
Slide 3: Revive Therapeutics
REVIVE THERAPEUTICS Bucillamine Focused on the development Advancing novel use of of therapeutics for infectious Bucillamine for Long COVID diseases, bioweapons and and medical countermeasures substance abuse Psilocybin Robust patent portfolio Developing oral Psilocybin for covering methods and subs
Slide 4: Strategy
STRATEGY Clinical development Target Markets Intellectual Property FDA Designations • Bucillamine: • Infectious Diseases • Novel Uses • Orphan Drug • Long COVID • Nerve Agent Exposure • Medical • Formulations • Fast Track • Emerging infectious Countermeasures diseases • Delivery Systems • Breakthrou
Slide 5: Intellectual Property Portfolio
INTELLECTUAL PROPERTY PORTFOLIO Ti tl e P atent Ap p ln . N o. 62/991,996, PCT/CA2021/050350, CAD 3,172,170, US 17/912,597, Japan 2022- U se of Bu cilla min e in the T rea tme nt of In fec tiou s Dis e as e s, in clu ding C OVID-19 556099, EP21772039.0, South Korea 10-2022-7036230, Hong Kong 6202307
Slide 6: Product Pipeline
PRODUCT PIPELINE Focus on Infectious Diseases, Medial Countermeasures, Substance Abuse Product Indication Stage of Development Regulatory Status Bucillamine Infectious Diseases Determining next steps Completed Phase 3 (Oral Tablet) COVID-19 and international opps Bucillamine Infectious Diseases Phas
Slide 7: Infectious Disease Opportunity
INFECTIOUS DISEASE OPPORTUNITY Bucillamine potential for Bucillamine Revive’s clinical history Bucillamine scientific COVID-19 Safety Profile with Bucillamine rationale as an intervention for COVID-19 (see Appendix) • Potential treatment for reduction in • Well-known safety profile and prescribed •
Slide 8: Psychedelics Programs
PSYCHEDELICS PROGRAMS Psilocybin for Substance Abuse Disorders Program • Collaboration with University of Wisconsin-Madison for the clinical development of Methamphetamine use disorder Novel Psilocybin Biosynthesis Enzymatic Platform • Collaboration with NCSU, under Dr. Gavin Williams, to develop a
Slide 9: Formulation & Delivery Technology
FORMULATION & DELIVERY TECHNOLOGY Delivering naturally extracted and synthetic psychedelics DELIVERY SYSTEM Combines Tannin (antibacterial, antifungal, antioxidant, wound healing) and Chitosan (blood-clotting and antimicrobial) composites Releases (rapid, controlled, sustained), improved bioavailabi
Slide 10: Strategic Partners
STRATEGIC PARTNERS Bucillamine Bucillamine Formulation Chemical Warfare Clinical Research Psilocybin Biosynthesis Psilocybin © COPYRIGHT 2025. Revive Therapeutics Ltd. ALL RIGHTS RESERVED.
Slide 11: Expected Milestones
EXPECTED MILESTONES Q2 Q3 2025 2025 • Results of Bucillamine for nerve • Interim-results of Phase 1/2 study agent exposure at DRDC for Psilocybin (Methamphetamine Use Disorder) at University of • FDA approval of Phase 2 study Wisconsin for Bucillamine to treat LONG COVID • Complete reformulation of
Slide 12: Team
TEAM Management Clinical & Regulatory Board of Directors • Michael Frank • Dr. Kelly McKee, Jr., MD, MPH • Michael Frank Chairman and CEO Chief Scientific Officer, Consultant Chairman and CEO • Carmelo Marrelli • Dr. Arshi Kizilbash, M.D. • William Jackson Chief Financial Officer Medical Advisor, Co
Slide 13: Stock Information
STOCK INFORMATION Ticker 52-Week High/Low Market Cap R V V (CSE) | R VV T F (OTCQB) | 31R (Frankfurt) CAD $0.035 / $0.005 CAD ~ $10,500,000 Share Price Capital Structure CAD $0.025 (May 20, 2025) 418,564,269 common shares 35,320,334 stock options 63,317,263 warrants ($0.05 - $0.20) © COPYRIGHT 2025.
Slide 14: Appendix – Bucillamine Scientific Rationale for COVID-19
APPENDIX – BUCILLAMINE SCIENTIFIC RATIONALE FOR COVID-19 Current antiviral interventions for influenza have exhibited modest efficacy, especially in improving mortality in at-risk populations, such as the elderly.1,2 Novel antivirals have been plagued by poor oral bioavailability and lack of efficac
Slide 15: Appendix – Bucillamine Scientific Rationale for COVID-19 (References)
APPENDIX – BUCILLAMINE SCIENTIFIC RATIONALE FOR COVID-19 References 1. Muthuri SG, Venkatesan S, Myles PR et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data